EDAP Secures €36M Credit Facility for Robotic HIFU Expansion
ByAinvest
Tuesday, Aug 26, 2025 9:49 pm ET1min read
EDAP--
The low-interest funding, accessible in tranches, will strengthen EDAP's balance sheet and provide a substantial source of capital to support its growth initiatives. CEO Ryan Rhodes expressed confidence that this financial support will enhance growth initiatives and expand access to their innovative technology [2].
EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices using ultrasound technology. The Focal One® technology is the leading prostate focal therapy controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer [2].
This strategic financing aligns with EDAP's mission to deliver innovative technologies for the benefit of millions of patients across the globe. The EIB has been a key partner in supporting such initiatives, providing low-interest funding that can be accessed in tranches as needed [1][2].
References:
[1] https://seekingalpha.com/news/4489116-edap-executes-letter-of-intent-for-36m-financing-from-european-investment-bank
[2] https://www.stocktitan.net/news/EDAP/edap-announces-letter-of-intent-for-36-million-euro-credit-facility-2ymdylq9plat.html
EDAP TMS SA secured a €36 million credit facility from the European Investment Bank to expand Focal One Robotic HIFU technology for early-stage prostate cancer treatment. The low-interest funding, accessible in tranches, will strengthen EDAP's balance sheet and accelerate the development of new clinical indications. CEO Ryan Rhodes expressed confidence that this financial support will enhance growth initiatives and expand access to their innovative technology.
EDAP TMS SA (NASDAQ: EDAP), a leader in robotic energy-based therapies, has secured a €36 million credit facility from the European Investment Bank (EIB). The financing, expected to close by the end of 2025, will support the continued expansion of Focal One Robotic HIFU in Focal Therapy, a treatment category for early-stage prostate cancer, and accelerate the development of new clinical indications [1][2].The low-interest funding, accessible in tranches, will strengthen EDAP's balance sheet and provide a substantial source of capital to support its growth initiatives. CEO Ryan Rhodes expressed confidence that this financial support will enhance growth initiatives and expand access to their innovative technology [2].
EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices using ultrasound technology. The Focal One® technology is the leading prostate focal therapy controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer [2].
This strategic financing aligns with EDAP's mission to deliver innovative technologies for the benefit of millions of patients across the globe. The EIB has been a key partner in supporting such initiatives, providing low-interest funding that can be accessed in tranches as needed [1][2].
References:
[1] https://seekingalpha.com/news/4489116-edap-executes-letter-of-intent-for-36m-financing-from-european-investment-bank
[2] https://www.stocktitan.net/news/EDAP/edap-announces-letter-of-intent-for-36-million-euro-credit-facility-2ymdylq9plat.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet